Viking Therapeutics is a clinical-stage biopharmaceutical company dedicated to developing novel therapies for metabolic and endocrine disorders. Their pipeline includes VK2809, an orally available thyroid hormone receptor beta agonist targeting non-alcoholic steatohepatitis (NASH) and fibrosis, and VK2735, a dual agonist of GLP-1 and GIP receptors aimed at treating obesity and related metabolic conditions. Viking's commitment to advancing innovative treatments addresses significant unmet medical needs, striving to improve patient outcomes in metabolic health.